EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Lowered to $33.00 at HC Wainwright

EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its target price reduced by HC Wainwright from $35.00 to $33.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.40) EPS, FY2023 earnings at ($1.89) […]

Related Keywords

,Eyepoint Pharmaceuticals Inc ,Securities Exchange Commission ,Analyst Recommendations For Eyepoint Pharmaceuticals ,Eyepoint Pharmaceuticals Stock Performance ,Eyepoint Pharmaceuticals ,Jpmorgan Chase Co ,Institutional Trading Of Eyepoint Pharmaceuticals ,York Mellon Corp ,Blackrock Inc ,News Ratings For Eyepoint Pharmaceuticals Daily ,Metlife Investment Management ,Free Report ,Capital One Financial ,Moderate Buy ,Point Pharmaceuticals ,Get Free Report ,Director Ye Liu ,Exchange Commission ,Cormorant Asset Management ,New York Mellon Corp ,Life Investment Management ,Eyepoint Pharmaceuticals Daily ,Nasdaq Eypt ,Eypt ,Medical ,Lower Price Target ,Hc Wainwright ,